Free Trial
ETR:EVT

Evotec (EVT) Stock Price, News & Analysis

Evotec logo
€6.00 -0.08 (-1.23%)
As of 03/28/2025

About Evotec Stock (ETR:EVT)

Key Stats

Today's Range
€5.92
€6.09
50-Day Range
€6.08
€9.03
52-Week Range
€5.06
€21.69
Volume
661,983 shs
Average Volume
1.36 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
2.63%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Remove Ads
Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVT Stock News Headlines

Evotec Aktie: Ratlosigkeit greift um sich?
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Evotec Aktie: Fragen bleiben offen
Biotech Report: Biontech und Evotec geben wieder ab
Evotec Aktie: Der Kampf um die Wende - verloren?
Evotec-Aktie: Jetzt könnte die Lage heikel werden
See More Headlines

EVT Stock Analysis - Frequently Asked Questions

Evotec's stock was trading at €8.20 at the beginning of 2025. Since then, EVT shares have decreased by 26.8% and is now trading at €6.00.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evotec investors own include Bank of America (BAC), Evotec (EVTCY), Intel (INTC), NVIDIA (NVDA), AbbVie (ABBV), Applied Materials (AMAT) and KLA (KLAC).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Financial Services
Current Symbol
ETR:EVT
CIK
N/A
Fax
N/A
Employees
5,061
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
69.91
P/E Growth
0.98
Net Income
$-179,291,392.78
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$812.97 million
Cash Flow
€1.74 per share
Price / Cash Flow
3.45
Book Value
€5.46 per share
Price / Book
1.10

Miscellaneous

Free Float
N/A
Market Cap
$1.11 billion
Optionable
Not Optionable
Beta
1.05
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ETR:EVT) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners